Millendo Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 7

  • Investments
  • 3

Millendo Therapeutics General Information

Description

Developer of novel drugs designed for the treatment of endocrine diseases caused by hormone dysregulation. The company pursues distinct and transformative treatments and leverage scientific advances to develop novel compounds to treat complex conditions and advance clinical care, enabling patients, families, and caregivers to live fuller lives.

Contact Information

Formerly Known As
Atterocor, Atterocor, Inc.
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 110 Miller Avenue
  • Suite 100
  • Ann Arbor, MI 48104
  • United States
+1 (734)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 110 Miller Avenue
  • Suite 100
  • Ann Arbor, MI 48104
  • United States
+1 (734)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Millendo Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Millendo Therapeutics‘s full profile, request access.

Request a free trial

Millendo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel drugs designed for the treatment of endocrine diseases caused by hormone dysregulation. The company p
Biotechnology
Ann Arbor, MI
7 As of 2021

King Of Prussia, PA
 

Vienna, Austria
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Millendo Therapeutics Competitors (4)

One of Millendo Therapeutics’s 4 competitors is CSL Behring, a Corporation company based in King Of Prussia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CSL Behring Corporation King Of Prussia, PA
CSL Behring (Biotechnology) Corporation Vienna, Austria
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Kedrion Private Equity-Backed Barga, Italy
To view Millendo Therapeutics’s complete competitors history, request access »

Millendo Therapeutics Patents

Millendo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021030335-A1 A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof Inactive 12-Aug-2019
WO-2017011302-A1 Enhanced bioavailability of n-(2,6-bis(1-methylethyl) phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl) methyl)urea hydrochloride Inactive 10-Jul-2015
WO-2016164476-A3 Combination of an acat1 inhibitor and a cyp1 1 b1 inhibitor for treating disorders associated with excess cortisol production Inactive 06-Apr-2015
US-20160287565-A1 Combination therapy for treating disorders associated with excess cortisol production Inactive 06-Apr-2015
WO-2016164476-A2 Combination therapy for treating disorders associated with excess cortisol production Inactive 06-Apr-2015 A61K31/444
To view Millendo Therapeutics’s complete patent history, request access »

Millendo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Millendo Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Millendo Therapeutics‘s full profile, request access.

Request a free trial

Millendo Therapeutics Acquisitions (3)

Millendo Therapeutics’s most recent deal was a Reverse Merger with Tempest Therapeutics. The deal was made on 28-Jun-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tempest Therapeutics 28-Jun-2021 Reverse Merger Drug Discovery
OvaScience 07-Dec-2018 Merger/Acquisition Biotechnology
Alizé Pharma 20-Dec-2017 Merger/Acquisition Pharmaceuticals
To view Millendo Therapeutics’s complete acquisitions history, request access »

Millendo Therapeutics Exits (1)

Millendo Therapeutics’s most recent exit was on 28-Jun-2021 from Tempest Therapeutics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Tempest Therapeutics 28-Jun-2021 Completed
To view Millendo Therapeutics’s complete exits history, request access »

Millendo Therapeutics FAQs

  • When was Millendo Therapeutics founded?

    Millendo Therapeutics was founded in 2011.

  • Where is Millendo Therapeutics headquartered?

    Millendo Therapeutics is headquartered in Ann Arbor, MI.

  • What is the size of Millendo Therapeutics?

    Millendo Therapeutics has 7 total employees.

  • What industry is Millendo Therapeutics in?

    Millendo Therapeutics’s primary industry is Biotechnology.

  • Is Millendo Therapeutics a private or public company?

    Millendo Therapeutics is a Private company.

  • What is Millendo Therapeutics’s current revenue?

    The current revenue for Millendo Therapeutics is .

  • How much funding has Millendo Therapeutics raised over time?

    Millendo Therapeutics has raised $131M.

  • Who are Millendo Therapeutics’s investors?

    5AM Ventures, Adams Street Partners, Altitude Life Science Ventures, Ann Arbor SPARK, and AstraZeneca are 5 of 18 investors who have invested in Millendo Therapeutics.

  • Who are Millendo Therapeutics’s competitors?

    CSL Behring, CSL Behring (Biotechnology), Genetix Biotherapeutics, and Kedrion are competitors of Millendo Therapeutics.

  • When was Millendo Therapeutics acquired?

    Millendo Therapeutics was acquired on 25-Jun-2021.

  • Who acquired Millendo Therapeutics?

    Millendo Therapeutics was acquired by Tempest Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process